List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1299 studies with search of: Doxorubicin OR liposomal OR Doxil[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
2 Completed Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
3 Completed Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Filgrastim;   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
4 Active, not recruiting A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
5 Completed A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
6 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
7 Recruiting A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B2: AMG 386 3mg/kg + Topotecan;   Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin;   Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
8 Active, not recruiting Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Intervention: Drug: temsirolimus & pegylated liposomal doxorubicin
9 Terminated Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: CC-5013;   Drug: liposomal doxorubicin
10 Active, not recruiting Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Intervention: Drug: M200 (Volociximab), Doxorubicin
11 Recruiting A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
12 Completed Ph 3 Randomized Study of Telcyta® + Liposomal Doxorubicin Vs Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: TLK286 (Telcyta) HCI for Injection;   Drug: Doxorubicin HCI Liposome Injection
13 Recruiting A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
14 Active, not recruiting Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Liposomal doxorubicin;   Drug: Cisplatin
15 Recruiting Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
16 Recruiting Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
17 Active, not recruiting The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (Study P04445AM2)
Condition: Breast Cancer
Interventions: Drug: Pegylated liposomal doxorubicin (SCH 66336);   Drug: Capecitabine
18 Recruiting Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Condition: Advanced Cancer
Interventions: Drug: Cisplatin;   Drug: Liposomal Doxorubicin
19 Completed Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Conditions: Cancer;   Carcinoma
Intervention: Drug: liposomal doxorubicin and docetaxel
20 Completed Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Pegylated Liposomal Doxorubicine

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services